Coherus presents preliminary unaudited FY2023 revenue at JPM conference; no specifics in filing

Coherus Oncology, Inc.

2023-FY EPS reported -$2.53 revenue$257,244,000

Preliminary unaudited FY2023 revenue presented at 42nd Annual J.P. Morgan Healthcare Conference.
Financial closing procedures not yet complete; final results may materially differ.
Independent registered public accounting firm has not reviewed the preliminary data.
Filing includes cautionary note about the preliminary nature of the results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Coherus Oncology, Inc. reported preliminary financial results for fiscal year ended December 31, 2023.

Period: fiscal year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 10, 2024, Coherus BioSciences, Inc. (the “Company”) will present its preliminary unaudited revenue for the fiscal year ended December 31, 2023 in a public webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in such presentation is furnished as Exhibit 99.1 to this report and will be available on the Company’s investor relations website at www.investors.coherus.com as previously announced.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-000166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.